Justin Klee is the Co-Chief Executive Officer and Director at Amylyx Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Klee co-founded Amylyx in 2013 with his Harvard College classmate Joshua Cohen, driven by a shared passion for addressing unmet medical needs in ALS after learning about the disease during their undergraduate studies in neuroscience. Before launching the company, Klee honed his expertise through academic research and early entrepreneurial ventures, blending scientific rigor with business acumen to translate promising compounds into potential treatments. Under Klee's leadership, Amylyx has achieved landmark milestones, including the U.S. FDA approval of RELYVRIO® (sodium phenylbutyrate/taurursodiol) in September 2022—the first new ALS therapy approved in five years—based on positive results from the CENTAUR trial demonstrating slowed functional decline. Klee played a pivotal role in securing over $400 million through the company's 2021 Nasdaq IPO, fueling pipeline expansion and global regulatory submissions, such as Health Canada's approval of RELYVRIO. His strategic oversight has positioned Amylyx as a leader in neurodegeneration, with ongoing Phase 3 trials like PHOENIX and AMX0035 for Alzheimer's disease. As Co-CEO, Klee directs overall strategy, operations, and business development, emphasizing patient-centric innovation and rapid advancement of therapies like AMX0114 for Wolfram syndrome. His visionary approach, recognized by Forbes' 30 Under 30 in Healthcare list, continues to drive Amylyx's mission to transform lives for those facing devastating neurological conditions.